Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Summit Therapeutics Inc.
Headquarters: Cambridge, MA, United States of America
Website: https://www.summittxinc.com/...
Year Founded: 2003
Status: Public
Industry Sector: HealthTechnology
CEO: Robert William Duggan; Mahkam Zanganeh, DDS, MBA
Number Of Employees: 159
Enterprise Value: $12,416,924,489
PE Ratio: -54.1
Exchange/Ticker 1: NASDAQ:SMMT
Exchange/Ticker 2: N/A
Latest Market Cap: $12,775,683,072
BioCentury | Apr 8, 2025
Product Development
VEGF multispecifics get innovative at AACR 2025
New binding domains, target combinations and molecule structures define the VEGF multispecifics to be presented at AACR 2025
BioCentury | Apr 8, 2025
Data Byte
The expanding pipeline of VEGF multispecifics
At least 35 VEGF multispecific programs are in development
BioCentury | Jan 29, 2025
Guest Commentary
Winning over Wall Street: Biotechs’ comeback playbook — a Guest Commentary by Jami Rubin
Advice for CEOs and CFOs as they navigate the year ahead
BioCentury | Jan 22, 2025
Finance
2025 Biotech Preview: Markets, Catalysts and AI
Assessing the bull and bear arguments and the catalysts for biotech in the New Year
BioCentury | Jan 18, 2025
Product Development
2025 catalysts: Bispecifics poised to enter new era
Decade after first approval, bispecifics on the precipice of going mainstream
BioCentury | Dec 19, 2024
Emerging Company Profile
Ottimo: Differentiating from the VEGF bispecific pack via VEGFR-2
Newco, led by ex-Seagen CEO Epstein, announces $140M series A
BioCentury | Nov 19, 2024
Politics, Policy & Law
RFK Jr. & HHS, Blenrep’s comeback, China deals: a BioCentury podcast
One editor’s take on why a Kennedy-led HHS would be disastrous for FDA, biopharma and patients
BioCentury | Nov 14, 2024
Deals
More BD in Akeso’s wake: Merck buys into LaNova’s bispecific for $588M up front
Marketer of Keytruda takes rights to bifunctional molecule in class that could compete directly with its top seller
BioCentury | Nov 14, 2024
Data Byte
Cross-border trends in uncertain times for China biotech
A new start-up model and licensing deals fueled by new modalities sustain the momentum of China biotech’s innovation engine
BioCentury | Nov 14, 2024
Deals
Already partners on bispecific, BioNTech buys Biotheus for $800M
Along with potential Keytruda competitor, German biotech gains pipeline, bispecific platform, and China sites via acquisition
Items per page:
1 - 10 of 58